Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02415413
Other study ID # GEM-CESAR
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date May 2015
Est. completion date June 2027

Study information

Verified date September 2022
Source PETHEMA Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.


Description:

This clinical trial is a multicenter Phase II study designed to evaluate the efficacy and toxicity of an intensive therapeutic approach in 90 patients with asymptomatic high risk multiple myeloma (SMM). 1. - Patients will receive an induction treatment consisting of 6 cycles of carfilzomib, lenalidomide and low-dose dexamethasone (KRd): patients will receive carfilzomib 20-36 mg/m2 IV on days 1, 2, 8, 9, 15 and 16; with oral lenalidomide 25 mg daily on days 1-21, subsequently there will be a rest period of a week (from day 22 to day 27). Moreover, oral dexamethasone 40mg daily will be administered weekly (days 1, 8, 15 and 22). 2. - Following the induction treatment, patients will receive high-dose (200 mg/m2) melphalan-based treatment administered via the intravenous route followed by peripheral blood stem cell transplantation (HDT-ASCT). 3. - The consolidation treatment will consist of 2 cycles of KRd, with the same doses and scheduled of the induction treatment. 4. - Maintenance treatment: all patients, without progression to symptomatic multiple myeloma or toxicity requiring discontinuation of the trial, will receive maintenance treatment during 24 cycles. This maintenance treatment comprises the administration of lenalidomide 10mg on days 1-21, followed by a rest period of 1 week, with the weekly administration of dexamethasone 20mg. Treatment will be administrated until the end of the maintenance, although patients will continue in the trial. If biological progression is observed following the discontinuation of the treatment, lenalidomide and dexamethasone will be reinstituted in order to control the disease again. Lenalidomide 10 mg will be administrated on days 1-21 combined with dexamethasone 20mg on days 1, 8, 15 and 22. All patients will be monitored for asymptomatic disease progression and to collect data regarding on overall survival (OS).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date June 2027
Est. primary completion date July 5, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - In the investigator's opinion, the patient must be able to fulfill all the clinical trial requirements. - The patient must voluntarily sign the informed consent before any study procedure that is not part of the standard of care for these patients is performed, with the patient's knowledge that he/she may withdraw from the study at any time, without prejudice to his/her future care. - The patient must be aged between 18 and 70 years, and eligible to receive high-dose therapy and autologous peripheral blood stem cell transplant. - The patient must be diagnosed with smoldering multiple myeloma at high risk of progressing to symptomatic multiple myeloma, or at ultra high risk of progression to symptomatic disease, defined by: - smoldering multiple myeloma at high risk of progression to symptomatic disease: Bone marrow infiltration with plasma cells (PCs) greater than or equal 10% and presence of a monoclonal component, immunoglobulin G (IgG) greater than3 g/dL or IgA greater than 2 g/dL or Bence Jones proteinuria greater than 1 g/24h and absence of lytic lesions, hypercalcemia, renal failure (creatinine less than 2 mg/dL) and anemia (hemoglobin greater than 10 gr/dL or not 2 gr/dL below the lower limit of normal). Bone marrow infiltration with PCs greater than or equal 10% OR IgG greater than 3 g/dL or immunoglobulin A (IgA) greater than 2 g/dL or Bence Jones proteinuria greater than 1g/24h (but not both together) and always in the absence of lytic lesions, hypercalcemia, renal failure and anemia. These patients may be included in the study if they meet the following additional criteria: A percentage of phenotypically aberrant plasma cells (PCs) within the bone marrow (BM) PC compartment (aPC/ BM PC) greater than or equal 95% and immunoapheresis, defined as a reduction in the levels of 1 or 2 immunoglobulin (Igs) of more than 25% compared with the normal values of the corresponding Ig. - smoldering multiple myeloma at ultra high risk of progression to symptomatic disease: Presence of more than 1 focal lesion in MRI (ideally whole body MRI). Infiltration in the BM equal or higher than 60%. Ratio of involved/uninvolved serum Friend leukemia cell (FLC) higher than 100. - The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status less than 2. - The patient must be able to attend the scheduled visits. - Women of childbearing potential must have a negative pregnancy test (serum or urine) within the 14 days before the starting the study drug. In addition, sexually active women must agree to use contraceptive methods (hormone contraceptives [oral, injectable or implanted], tubal ligation, intrauterine device, barrier contraceptives with spermicide or have a vasectomised partner) while receiving the study drug. Women of childbearing potential must agree to undergo pregnancy tests every 4 weeks while receiving the study drug (every 14 days for women with irregular menstrual cycles) and 4 weeks after the last dose of study drug. Exclusion Criteria: - Any physical condition or psychiatric disorder that would prevent the patient from signing or understanding the informed consent form. - Previous treatment for smoldering multiple myeloma. - Pregnancy or breastfeeding. - Presence of lytic lesions, anemia, renal failure or hypercalcemia. - Any of the following laboratory abnormalities: Absolute neutrophil count (ANC) less than 1,000/mm3 Platelet count less than 75,000/mm3. Serum GOT or glutamic pyruvic transaminase (GPT) greater than 3 x upper limit of normal Serum total bilirubin greater than 2 x upper limit of normal - Prior history of neoplasm other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the patient has been disease-free for > 5 years. - Major surgery within 4 weeks before inclusion in the study. - Known active infection by human acquired immunodeficiency virus, B or C hepatitis virus. - Any investigational drug within 30 days before inclusion in the study. - Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrolment. - Unstable angina or myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker. - Uncontrolled hypertension or uncontrolled diabetes. - Significant neuropathy (Grades 3?4, or Grade 2 with pain) within 14 days prior to enrollment. - Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib). - Contraindication to any of the required concomitant drugs or supportive treatments, including intolerance to hydration due to pre-existing pulmonary or cardiac impairment. - Left ventricular ejection fraction (LVEF) less than 40 - Pulmonary hypertension

Study Design


Intervention

Drug:
carfilzomib

Lenalidomide

Dexamethasone

Melphalan


Locations

Country Name City State
Spain Hospital Clínic de Barcelona Barcelona
Spain Hospital Universitari Germans Trias i Pujol Barcelona
Spain Hospital Clínico San Carlos Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Ramón y Cajal Madrid
Spain Hospital Universitario Morales Meseguer Murcia
Spain Hospital Universitario Central de Asturias Oviedo
Spain Clínica Universidad de Navarra Pamplona
Spain Hospital de Son Llàtzer Plama De Mallorca
Spain Hospital Universitario de Salamanca Salamanca
Spain Hospital Universitario Reina Sofía Sevilla
Spain Hospital Universitario Virgen del Rocío Sevilla
Spain Hospital Universitario de Canarias Tenerife
Spain Hospital Clínico Universitario de Valencia Valencia
Spain Hospital Universitario Doctor Peset Valencia
Spain Hospital Clínico Universitario Lozano Blesa Zaragoza

Sponsors (3)

Lead Sponsor Collaborator
PETHEMA Foundation Amgen, Celgene Corporation

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT 4 months
Secondary Efficacy - Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance Number of Response rates after the different parts of the treatment, induction, HDT-ASCT, consolidation and maintenance up to 24 weeks
Secondary Efficacy- Months to progression free survival Months to progression free survival 60 months
Secondary Efficacy -Months to overall survival Months to overall survival 60 months
Secondary Relapse or progression patterns in the group of patients requiring a rescue therapy after june 2020. Relapse or progression patterns after first line treatment with KRd->PBPCT->KRd->Rd, in the group of patients requiring a rescue therapy after june 2020. Up to 84 months (from june 2020)
Secondary Response rate of rescue therapy in the group of patients requiring a rescue therapy after june 2020. Response rate achieved with daratumumab, pomalidomide and dexamethasone (DPd) as rescue therapy, by evaluating all response categories, including immunophenotypic response, sCR, CR, VGPR, PR and SD. Up to 84 months (from june 2020)
Secondary Progression Free Survival (PFS) and Overall Survival (OS) from the date of relapse / progression of disease PFS and OS from the date of relapse / progression of disease, in the group of patients requiring a rescue therapy. Up to 84 months (from june 2020)
Secondary Biological studies in the group of patients requiring a rescue therapy. Phenotypic and molecular assessment of the tumor clone that appears in the moment of relapse or disease progression (DP), and comparison against the tumor clone characterized at the moment of inclusion in the first part of the trial. Up to 84 months (from june 2020)
Secondary Study of patient immune profile in the group of patients requiring a rescue therapy. Assessment of patient immune profile at the moment of inclusion in this modification, and assessment of evolution under DPd treatment. Up to 84 months (from june 2020)
Secondary Study of patient immune profile depending on type of relapse, in the group of patients requiring a rescue therapy. Assessment of immune profile at the moment of inclusion in patients in biochemical relapse vs. those in symptomatic relapse. Up to 84 months (from june 2020)
See also
  Status Clinical Trial Phase
Completed NCT01222286 - Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma Phase 2
Withdrawn NCT00503763 - Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma Phase 2
Active, not recruiting NCT02916771 - Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Phase 2
Completed NCT01955395 - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma N/A
Completed NCT01237054 - Imaging in MGUS, SMM and MM Phase 2
Completed NCT02903381 - A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma Phase 2
Active, not recruiting NCT03301220 - A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Phase 3
Active, not recruiting NCT03236428 - Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Phase 2
Completed NCT01718899 - Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Phase 1
Completed NCT00099047 - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Phase 2
Completed NCT00112827 - Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma Phase 1/Phase 2
Terminated NCT01248455 - A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma Phase 2
Active, not recruiting NCT03289299 - Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant Phase 2
Not yet recruiting NCT06365060 - Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Completed NCT01302886 - Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma Phase 2
Recruiting NCT05841550 - The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma Phase 1/Phase 2
Recruiting NCT06183489 - Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma Phase 2
Recruiting NCT06383143 - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Active, not recruiting NCT02886065 - A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM Phase 1
Withdrawn NCT01571726 - Imaging Studies and the Development of Multiple Myeloma Phase 2